首页> 外文期刊>Clinical, Cosmetic and Investigational Dermatology >Recurrent candidal intertrigo: challenges and solutions
【24h】

Recurrent candidal intertrigo: challenges and solutions

机译:经常性候选人互联器:挑战和解决方案

获取原文
       

摘要

Intertrigo is a common inflammatory dermatosis of opposing skin surfaces that can be caused by a variety of infectious agents, most notably candida, under the effect of mechanical and environmental factors. Symptoms such as pain and itching significantly decrease quality of life, leading to high morbidity. A multitude of predisposing factors, particularly obesity, diabetes mellitus, and immunosuppressive conditions facilitate both the occurrence and recurrence of the disease. The diagnosis of candidal intertrigo is usually based on clinical appearance. However, a range of laboratory studies from simple tests to advanced methods can be carried out to confirm the diagnosis. Such tests are especially useful in treatment-resistant or recurrent cases for establishing a differential diagnosis. The first and key step of management is identification and correction of predisposing factors. Patients should be encouraged to lose weight, followed up properly after endocrinologic treatment and intestinal colonization or peri-orificial infections should be medically managed, especially in recurrent and resistant cases. Medical treatment of candidal intertrigo usually requires topical administration of nystatin and azole group antifungals. In this context, it is also possible to use magistral remedies safely and effectively. In case of predisposing immunosuppressive conditions or generalized infections, novel systemic agents with higher potency may be required.
机译:Intertrigo是一种常见的炎性皮肤病,其相对的皮肤表面可以是由机械和环境因素的影响而引起的各种传染病,最典型的念珠菌引起的。症状如疼痛和瘙痒显着降低了生活质量,导致高发病率。多种易估计因素,特别是肥胖,糖尿病和免疫抑制条件促进了疾病的发生和复发。候选互联器的诊断通常基于临床外观。然而,可以进行一系列从简单测试到先进方法的实验室研究以确认诊断。这种测试特别适用于用于建立鉴别诊断的治疗或复发性案例。管理的第一步和关键步骤是识别和纠正易感因素。应鼓励患者减肥,在内分泌治疗和肠道殖民化或肠道殖民化或肠梗理感染后进行随访,特别是在经常性和抗性病例中。候选互联器的医学治疗通常需要局部施用Nystatin和唑类抗真菌。在这种情况下,还可以安全有效地使用杂项疗法。在预测免疫抑制条件或广义感染的情况下,可能需要具有较高效力的新型全身性药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号